Comparative costs and activity from a sample of UK clinical trials units by Hind, Daniel et al.
                          Hind, D., Reeves, B., Bathers, S., Bray, C., Corkhill, A., Hayward, C., ...
Bradburn, M. J. (2017). Comparative costs and activity from a sample of UK
clinical trials units. Trials, 18, [203]. DOI: 10.1186/s13063-017-1934-3
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1186/s13063-017-1934-3
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BioMed Central at
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-1934-3. Please refer to any applicable terms
of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
RESEARCH Open Access
Comparative costs and activity from a
sample of UK clinical trials units
Daniel Hind1* , Barnaby C. Reeves2, Sarah Bathers3, Christopher Bray4, Andrea Corkhill5, Christopher Hayward6,
Lynda Harper7, Vicky Napp8, John Norrie9, Chris Speed10, Liz Tremain11, Nicola Keat12 and Mike Bradburn1
Abstract
Background: The costs of medical research are a concern. Clinical Trials Units (CTUs) need to better understand
variations in the costs of their activities.
Methods: Representatives of ten CTUs and two grant-awarding bodies pooled their experiences in discussions
over 1.5 years. Five of the CTUs provided estimates of, and written justification for, costs associated with CTU
activities required to implement an identical protocol. The protocol described a 5.5-year, nonpharmacological
randomized controlled trial (RCT) conducted at 20 centres. Direct and indirect costs, the number of full time equivalents
(FTEs) and the FTEs attracting overheads were compared and qualitative methods (unstructured interviews and thematic
analysis) were used to interpret the results. Four members of the group (funding-body representatives or award panel
members) reviewed the justification statements for transparency and information content. Separately, 163
activities common to trials were assigned to roles used by nine CTUs; the consistency of role delineation was
assessed by Cohen’s κ.
Results: Median full economic cost of CTU activities was £769,637 (range: £661,112 to £1,383,323). Indirect costs varied
considerably, accounting for between 15% and 59% (median 35%) of the full economic cost of the grant. Excluding one
CTU, which used external statisticians, the total number of FTEs ranged from 2.0 to 3.0; total FTEs attracting overheads
ranged from 0.3 to 2.0. Variation in directly incurred staff costs depended on whether CTUs: supported particular roles
from core funding rather than grants; opted not to cost certain activities into the grant; assigned clerical or data
management tasks to research or administrative staff; employed extensive on-site monitoring strategies (also the
main source of variation in non-staff costs). Funders preferred written justifications of costs that described both
FTEs and indicative tasks for funded roles, with itemised non-staff costs. Consistency in role delineation was fair
(κ = 0.21–0.40) for statisticians/data managers and poor for other roles (κ < 0.20).
Conclusions: Some variation in costs is due to factors outside the control of CTUs such as access to core funding
and levels of indirect costs levied by host institutions. Research is needed on strategies to control costs appropriately,
especially the implementation of risk-based monitoring strategies.
Background
The increasing costs of clinical trials, of great concern a
decade ago [1, 2], continue to be the subject of comment
and debate worldwide [3–11] despite some indications
of freezes or cuts in funding since the onset of the global
recession in 2008 [12, 13]. The costs and delays associ-
ated with a steady increase in bureaucracy in Europe
and America are well-attested [14–30]. The extent to
which increasing trial complexity has been responsible
for driving up costs has also been the subject of scrutiny,
with documented increases in the numbers of trial pro-
cesses and eligibility criteria [31–33]. Some claim that in-
cremental increases in complexity are not always matched
by a corresponding increase in staffing [33–35], and that
this can lead to staff burnout and attrition as well as chal-
lenges associated with crisis management [34, 36].
Clinical trials units (CTUs) are specialised research
entities that may assist with the design and central co-
ordination of trials [37]. The case has been made for
CTUs being central to the maintenance of quality, cred-
ibility and impact of clinical trials [38, 39], and their
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costs are already the subject of research publications
[37, 39]. Previous work has identified research activities
associated with clinical trials and the key determinants
of their cost [37]. The purpose of the present work is to
provide evidence of, and rationales for, variations in the
cost of those activities between units based on the ex-
periences of ten UK CTUs.
Methods
Between March 2013 and June 2014 the authors pooled
their experiences at four 2-h teleconferences, two full-
day workshops and intermittent e-mail contact. Three
more formal pieces of research were also designed, to
help the group to pool their experiences and expertise.
One investigated variation in costs of CTU-based activ-
ities, a second involved written justifications of the costs,
and a third considered differences in role delineation
across CTUs.
Variation in costs
CTUs based in higher education institutions (HEIs)
volunteered to cost CTU activities for the same proto-
col given in vignette form (Additional file 1). CTUs
were asked to budget only for their own research costs,
that is, including monitoring carried out by the CTU, but
excluding research activities carried out by centres such as
the collection and entry of data by research nurses. The
protocol specified a 66-month surgical trial, timetabled to
run between 1 January 2015 and 30 June 2020 with 12
months’ set-up, 24 months’ recruitment, 24 months’
follow-up and 6 months’ close-out. It assumed that four
centres would open each month between months 8 and
12 and the first operations would be carried out on rando-
mised participants between months 13 and 17. Centres
were projected to identify on average 1.3 eligible partic-
ipants per centre, per month, of whom 45% would
consent.
The direct costs of implementing a trial by a CTU are
conventionally divided into staff and non-staff costs.
Salary details reported by CTUs were institution-specific
for the financial year 2013–2014; profiles of staff grades and
spine points were chosen by the CTUs undertaking the ex-
ercise; professorial salaries can vary substantially (£60,000
to £110,000). Summary costs were tabulated using the
Transparent Approach to Costing (TRAC) categories [40].
In the UK, staff costs are currently classified as directly allo-
cated or directly incurred (representing services incurred or
purchased specifically for a project). Increasingly, CTUs are
hosted by HEIs and directly allocated costs will typically
cover Higher Education Funding Council for England
(HEFCE-)funded university staff who would otherwise be
deployed on legitimate HEI activities such as teaching. In-
direct and estate costs (collectively referred to as indirect
below) are defined as those ‘not directly related to any one
project or activity, but [which] are a necessary part of the
costs of undertaking an activity’ [40]. For a UK CTU hosted
by an HEI, the indirect costs associated with a research pro-
ject are related to their HEI’s infrastructure; they are typic-
ally calculated in relation to the number of researcher full
time equivalents (FTEs) (but not technical or administrative
staff) funded by the project. (NHS institutions cannot
charge indirect costs, only 100% of directly incurred costs;
none of the CTUs taking part costed for NHS staff).
Telephone interviews with CTU representatives who
performed the costings were conducted by the lead author
to elicit data on local practices and reasons why they might
produce costs that differed from those of other CTUs. We
had few preconceived opinions about reasons for varying
costs and we used unstructured interviews to collect data,
with no theoretical framework for its analysis [41, 42].
There were no topic guides, with the cost-specifications
themselves forming the basis for questions and discussion.
Interviews, which lasted between 30 and 60 min, were
digitally recorded and transcribed verbatim, with themes
derived inductively by the interviewer. Key themes which
arose during minuted meetings held between January 2013
and June 2014 were also incorporated into the results and
discussion. Because all interviewees were committee mem-
bers and coauthors, we considered the work to be exempt
from ethical approval and consent to be implied.
Justification of costs
CTUs that submitted costs were also asked to submit
justification of their costs within a 2000-character limit
typical of Grant Application Forms. These statements
were anonymised and given to four members of the
group not involved in the costings exercise, but who rep-
resented funding bodies or sat on funding panels. Infor-
mal feedback was elicited about the content and style
that was most helpful for allowing funders to judge the
appropriateness of the resources being requested.
Role delineation
The objective of this exercise was to describe variation
between CTUs in the allocation of particular CTU activ-
ities to staff roles. We assessed variation across CTUs
represented by members of the group on the involve-
ment of each role in each of 163 activities which would
be necessary in a clinical trial of an investigational medi-
cinal product. This list of activities had been drawn up
by the UK Trial Managers Network in 2009 (Additional
file 2). Activities were entered as the first column of a
spreadsheet. The exercise required CTU representatives
to insert their own job category titles across the top row –
taking as many columns as needed – and, for subsequent
rows, ticking whether each job category was involved in
carrying out the task in column A. Respondents could tick
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more than one job category for a particular activity as
many activities within trials are multidisciplinary.
We did not specify job titles a priori because we already
had a large volume of anecdotal evidence that: (1) job
titles differ from unit to unit, (2) where units have similar
job titles, it is unclear whether the roles are in fact the
same and (3) not all units employ, for example, people
called ‘programmers’ or ‘statisticians’ (minutes, 20 March
2013). Therefore, we allowed units to specify their own
job titles/roles and, when they generally allocated activities
in this way, to complete the form by allocating tasks to job
families rather than discrete job categories per se – a
shortcoming discussed below. By job families, we mean
groupings of CTU workers, whose task sets are subject-
ively thought to be closely related in functional terms. For
instance, one unit considered their trial manager, trial co-
ordinator and senior trial manager, all to be working in
‘trial management’ (minutes, 20 March 2013). The most
common job family terms across units were ‘statistics’,
‘study/trial management’, ‘data management’, ‘quality assur-
ance’ (QA) and ‘clerical/admin’, with other job families,
such as programming, not adopted by all units.
For each role, we used STATA v13 software to calculate
Cohen’s κ (kappa), a chance-corrected statistic in which a
value of 1 corresponds to perfect consistency, 0 to agree-
ment no better than chance alone, and negative values to
agreement worse than chance (STATA v13) [43]. We used
Altman’s benchmark scale to assess inter-rater reliability
[44]. A first analysis used a dataset in which the roles
defined by the CTUs were informally mapped to their
closest perceived equivalent roles at an index unit – the
analyst’s home unit, selected for convenience. We then
applied formal statistical tests of task-set agreement (see
columns B to J, Additional file 3). A number of roles at
the units, for instance ‘operations director’, had no obvious
equivalents across the majority of units and so were left
out of the analysis. A second analysis combined certain
roles into job families for those units which had not pre-
sented data in this way; this analysis was designed to ac-
count for fuzziness at the boundaries of related roles that
was reported by some units. The following roles were
combined: administrative and clerical; senior and junior
statistician; study manager and research assistant.
Results
Variation in costs
Summary results of the cost-comparison exercise are
displayed in Table 1. At four CTUs, standard practice
was to smooth the cost of variable across the study
period, which made budgetary projection easier; at one
CTU (A), variable costing was standard and has been
smoothed for the purposes of this report, except where
stated. Across the five CTUs, the median full economic
cost of CTU activity was £769,637 (range: £661,112 to
£1,383,323). Variation in overall costs were related to
whether, as well as how, particular activities were costed;
for instance, CTU D does not employ its own statisticians,
meaning that one could expect to see an additional cost for
non-CTU personnel to provide the statistical resource re-
quired for the trial. Across other CTUs, the median cost of
senior plus junior statisticians (not including statistical pro-
grammers where used) was £76,799 (£61,035 to £103,755).
The greatest variation between CTU costs was observed
in the level of indirect costs (median £301,412, range
£112,386 to £819,641), which accounted for between 15%
and 59% of the full economic cost (median 35%). CTU B,
whilst having median staff costs and the lowest non-staff
costs, had the highest overall costs due to the relatively
high level of indirect costs levied by its host institution
(59% of the full economic cost). Excluding the CTU which
did not provide statistical services at the time, the total
number of FTEs ranged from 2.0 to 3.0; the number of
FTEs attracting overheads ranged from 0.3 to 2.0.
A related issue was variation in the designation of pro-
ject staff. When TRAC methods are applied (see above),
HEI staff designated as researchers attract indirect costs
whilst other HEI staff and NHS-based staff do not. The
only roles which were consistently designated research
staff were the senior trial methodology advisory roles
(typically provided by a senior academic) and statisticians,
although it was rare for study managers and research as-
sistants to be on technical contracts. Data managers and
programmers were typically, but not always, on technical
contracts, with QA officers equally likely to be designated
as researchers or not.
The second largest source of variation was the dif-
ferences in staffing – although there were considerable
commonalities in the way some roles were costed. Several
over-arching issues emerged from interviews and from
discussions at teleconferences and meetings. These are
described first, followed by variation in staffing by job
family; in this section, annual salary costs are described.
Over-arching issues
Estimating the direct costs of a trial for a grant application
is an inexact exercise that tries to anticipate the resources
required based on specific trial factors (setting, number of
centres, sample size, recruitment rate, duration of inter-
vention, number of follow-up visits and total duration of
follow-up, outcomes to be measured, etc.).
The resources required for a trial are not constant
over time but are difficult to schedule since trials may
not run according to plan. Therefore, CTUs are typically
project-managing a specific trial (and budget) in the
context of a larger envelope of resources (and budget)
accruing over a portfolio of trials. This justifies budget-
ing for an average amount of resource for a job family of
activity for a trial and managing fluctuations in workload
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across multiple trials. CTUs with larger portfolios may
be able to achieve this flexibility more easily.
CTUs have markedly different histories and infrastruc-
ture affecting staff-mix, established ways of working, port-
folio size and activities they offer (potentially devolving
some activities outside the unit). These factors are largely
fixed but inevitably impact on the ways they manage and
budget for trials.
CTUs varied in their access to NIHR CTU Support
Funding (partly related to size and history), to charitable
‘infrastructure’ funding and to ‘core’ investment (directly
by HEIs because trials generate large amounts of income
through staff funded from other sources, such as medical
charities, but able to collaborate on trials, etc.). NIHR CTU
Support Funding is intended to be used to facilitate the
submission of more, higher-quality grant applications to
the NIHR but this and other resources, not derived from
grants, allow CTUs/HEIs flexibility in costing grant applica-
tions. Core investment (e.g. research fellowships) may cover
staff time, providing flexibility for a person to carry out re-
search within a broad designated health area (e.g. disease-
specific cancer; cardiovascular disease; arthritis).
Variation in staff costs by activity job family
Study management oversight by senior trials unit staff
was mainly at 5% throughout – with one CTU dropping
provision to 2% for the final 6 months and one CTU
opting for 10% throughout; the base salary for this role,
however, varied from £45,053 (often called a ‘research
fellow’) to a professorial level, although salaries in the
range £47,787 to £53,765 (‘senior research fellow’) were
most common. These individuals generally played a role
in proposal development and costing in the pre-award
phase, and, post award, supervision of study staff and
essential documentation, attendance at Trial Management
Groups, Trial Steering Committees and Data Monitoring
and Ethics Committees and interpretation and writing of
trial reports. Some had substantial core funding from
a variety of sources and some were wholly funded
from grants.
Project management was much more complicated and
heterogeneous with a wide variety of job titles and role
boundaries making direct comparison difficult (see below,
‘Role delineation’). The project manager would typically
be full time and have a salary in the range of £28,972 to
£36,661, with some CTUs capping salaries for this work at
just over £34,000. One CTU made considerable savings
over the course of the project by variable costing of study
managers, dropping the post from 100% to 40% during
the recruitment period once all centres were open and,
further, to 20% during the period in which patients were
only being followed up. The representative of this CTU
acknowledged that their unit benefitted from dependable
core/infrastructure funding and economies of scale not
available to many smaller units. These circumstances
meant that, in the event of unexpected problems with
governance or attrition which can take up time in the
later phases of a trial, there were always staff available
to deal with these problems effectively without including a
costing to cover this risk for individual trials:
‘For a lot of units it is very difficult to have that
fluctuation in work load within a project… it is about the
infrastructure and the set-up that you’ve got as a unit’.
Project management staff were not limited to the pro-
ject manager. One CTU budgeted for 25% of a more se-
nior project manager (salary in the range of £37,756 to
£45,053) in addition to the project manager themselves. It
was more common to see a proportion of a more junior
researcher, sometimes called a ‘research assistant’, to sup-
port the project manager.
Reassuringly, the level of funding for statistics varied
little between units. Aside from unit D (see above) statis-
tical support (excluding programming) was commonly at
30–33% throughout, with one unit preferring variable
costing (20% throughout, and 100% in the last 6 months)
of a junior statistician, usually salaried between £30,728
and £36,661. The junior statistician was typically sup-
ported by at least one senior statistician, typically at 5%
and with a salary in the range £42,476 to £53,765, al-
though occasionally the cost of this resource implied
that senior statistical oversight would be carried out by
someone on a much higher, professorial salary. Smooth-
ing of junior statistician salaries across grants was near
ubiquitous, despite more or less predictable peaks and
Table 1 Summary comparison of Clinical Trials Unit (CTU) costs for identical protocol
Trials unit 100%FEC D.A. D.I. Total staff costs (%) Non-staff costs (%) Indirect costs (%) Total FEC Total no. of FTEs
attracting overheads
Total number
of FTEs
A £0 £362,350 £362,350 (55) £65,375 (10) £233,387 (35) £661,112 0.89 2.00
B £53,608 £443,924 £497,532 (36) £66,150 (5) £819,641 (59) £1,383,323 0.43 3.00
C £0 £638,611 £638,611 (54) £131,776 (11) £411,684 (35) £1,182,071 2.00 3.00
D £0 £364,042 £364,042 (52) £39,914.02 (6) £301,412 (43) £705,368 1.43a 1.47a
E £0 £574,701 £574,701 (75) £82,550 (11) £112,386 (15) £769,637 0.3 2.49
a CTU D did not include costs for statistical design and analysis, as they used external statisticians
D.A.directly allocated, D.I.directly incurred, FEC, FTE full time equivalents
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troughs in activity (drafting the statistical analysis plan,
reports for oversight committees, interim analyses, final
analyses and write up).
The following rationale was given by one CTU repre-
sentative and accepted as legitimate by funding-body
representatives:
‘What CTUs are trying to do is to run a portfolio.
Within that, you recognise that, despite your best
intentions, trials have a life of their own. They very
rarely go according to the timeline that you set, they
very rarely go according to the budget that you set,
and nearly all of the funding is fixed. So, you have to
have 30% of a junior statistician. The point about
burnout of the junior statisticians is incredibly
important. If you keep loading them with four to six
studies and expect them to deliver excellence at a
relatively early part of their career, there can be
psychological harms and professional costs’.
Two CTUs did not budget for clerical officers and, in
each case, allocated what other CTUs saw as clerical
tasks (such as site file composition, minute-taking and
the processing of expenses claims) to research staff on
higher salaries. For one unit this was a choice; for the
other it was imposed on them by a host institution because
of perceived imbalances in the departmental staffing profile
(see above regarding designation of staff as researchers or
not and the impact on indirect costs):
‘A lot of our trial managers spend a lot of time being
very expensive administrators and secretaries so the
only way we seem to be able to address that is to
significantly increase the amount of assistant trial
manager time’.
When included, clerical salaries ranged from £15,456
to £21,597 and such staff were never designated as re-
searchers (and, therefore, did not attract indirect costs).
Those at the bottom end were typically associated with
data entry tasks and those at the top end were associated
with tasks allocated to research staff at other institutions
(site file composition, minute-taking, reimbursement of
cost claims, and budgetary support).
Data managers, typically on nonresearch salaries of
between £28,132 and £36,661, were budgeted at an aver-
age of 30% throughout most of a study, with some units
varying the amount of time for this role across the dur-
ation of the trial. In some CTUs the boundaries between
data management, data entry (more typically a junior re-
search or clerical post) and programming were often
‘fuzzy’. Some units assumed that research nurses would
input data on site (thus, a site cost rather than a CTU
cost), whilst others arranged for paper Case Report
Forms (CRFs) to be returned to the CTU for data entry.
One unit outsourced its programming for data manage-
ment, showing this activity in the budget as a consultancy
fee instead of a staff cost. At other units, there was great
variation in how programmers were costed in terms of
their salary ranges and the duration of their input on the
trial – with many costing this role only for 3 to 6 months
in the first year and some smoothing the costs through-
out. There was also some overlap in duties between data-
base programmers and statistical programmers at some
units, all of which made comparison difficult.
Quality assurance was an activity which was budgeted
for by three of the five CTUs. One CTU funded this activity
wholly from core/infrastructure funding; another had never
been able to fund a formal QA role from either core or
grant funding. A number of CTUs reported distributing
key QA tasks, such as risk assessment and the authorship/
update of standard operating procedures, across their staff,
because they were unable to fund a QA officer adequately.
Where present, QA officer salaries were in the range of
£21,597 to £34,575, with higher whole time equivalents
(WTEs) requested for junior (e.g. 20%) compared to senior
staff (e.g. 5%). QA officers were sometimes designated as
having academic and sometimes nonacademic contracts.
A breakdown of non-staff costs can be found in Table 2.
In two CTUs, travel costs associated with oversight (Trial
Steering and Data Monitoring) Committees (although
many units were increasing the use of teleconferences)
and, particularly, on-site monitoring accounted for two
thirds of all non-staff costs, compared to between 19%
and 30% of non-staff costs in other units. Most units re-
ported an increasing shift towards central monitoring
although some are still required by sponsors to perform
the majority of their monitoring on site. Some sponsors
still require on-site monitoring, partly because of concern
about the safety and effectiveness of central monitoring,
even in ostensibly low-risk studies and despite contrary
expert opinions [9, 45, 46].
‘… there’s always some rogue sites… and you can’t
underestimate the value of contact… for keeping the
study in the forefront of people’s minds.’
For the three units using proprietary, fee-based, elec-
tronic data capture systems (complementing, or instead of,
in-house data management staff), the fees were £5,500
(CTU A: not including £31,697 programmer costs), £7,500
(CTU D: not including programming undertaken as part of
the work of 0.3 WTE data managers) and £45,640 (CTU E:
not including £7,955 programmer costs). CTU E’s costs in-
cluded a database licence at £10,000 and £35,640 (£33 per
site, per month) for site access to the electronic CRF
(eCRF). The use of an eCRF with this cost structure is not
something for which the other CTUs had to cost. CTU A
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used paper CRFs at the centres, returned by post, resulting
in low database costs and above average consumable costs.
For commercial database systems with a flat fee workplace
licence, units with larger portfolios were able to achieve
greater economies of scale. Two units used programmers
to adapt or modify locally developed systems: CTU B at
£59,252 and CTU C at £23,800 – although, as with CTU
D, this figure masked a certain amount of additional pro-
gramming undertaken by data managers.
Justification of costs
Representatives of four CTUs submitted anonymised
statements justifying the costs they had submitted in the
exercise described above (Additional file 4). Representa-
tives of funders preferred a written justification of costs
that combined details of FTEs with indicative tasks for
given roles. They rated as most useful the submissions
from CTU A and CTU C, although the former lacked
detail on non-staff costs and the latter lacked detail on
the period of deployment of staff across the duration of
the trial. Funders preferred these submissions because
‘they enabled a fuller understanding of the activity to be
undertaken and enabled an informed assessment of the
financial costs and value for money’.
Role delineation
The units responded with an average of 7 job titles each,
ranging from 3 to 11 job titles across the units. Once
duplicates had been removed, there were 43 unique job
titles (see Table 3). Nine of these were felt to map
adequately across a number of units but, when tested
formally, consistency in the allocation of activities to
roles was fair (κ = 0.21–0.40) for senior statisticians and
data managers and poor for other roles (κ < 0.20) (Table 4;
Additional file 5). When we combined roles into job
families, consistency in the allocation of activities to
roles was fair for statisticians and data managers and
poor for other job families (Table 5). The role delinea-
tion exercise confirmed that micro-costing at the level
of the individual task is not feasible and that, for prag-
matic reasons, costing has to be taken at the level of
the role or job family, with the potential to vary or
smooth costs according to anticipated workload across
different periods of the study (minutes 15 July 2013).
Discussion
Summary of findings
This study confirms the subjective impression of grant
award panel members that CTU costs on grant applications
vary in ways that cannot be attributed wholly to study
design or complexity (held constant in this exercise by
use of the trial vignette). Levels of indirect costs levied
by HEIs, level of staffing requested (often related to the
size of the unit and its access to non-project-specific
funding, variably referred to as core/infrastructure fund-
ing), number of WTEs attracting overheads and level of
site-based monitoring activities were the main drivers of
variation in CTU costs.
Strengths and limitations of the study
The diverse perspectives of contributors to this study
(representing funders, members of grant award panels as
well as CTUs) is an important strength. CTU members
were chosen (from a larger number of nominees) for the
group on the basis of their stated expertise with respect
to costing research. Representatives of participating units
found no difficulties in costing the protocol and, whilst
noting differences in definition and attribution of costs
for the set-up period of a trial, confirmed that other
timescales were within what was considered normal
locally. The conduct of this exercise over 12–18 months,
with several opportunities for debate and feedback, is
another strength.
The main limitation of this exercise is the limited sample
size. The findings of this paper reflect the pooled experi-
ence of members from only ten of the 45 CTUs registered
with the UK Clinical Research Collaboration in 2013.
Although this sample of CTUs is diverse in terms of
funding, portfolios and organisation, it is unlikely that
they are fully representative of all UK units. In par-
ticular, the comparative costs exercise is based on de-
tailed feedback from a self-selected sample of just five
CTUs that were able to prioritise an unfunded contri-
bution to this exercise, fewer than considered satisfac-
tory for thematic saturation [47]. Our remit did not
permit a detailed discussion of the impact of access to
core infrastructure on the costs and activity of any
particular CTU, although the group felt that such
access had an important impact on research costs
Table 2 Non-staff costs
Trials unit A B C D E £ median (range) Median (range) %
of non-staff costs
Travel £19,380 (30%) £12,750 (19%) £88,190 (67%) £25,952 (65%) £17,004 (21%) £19,380 (12,750 to 88,190) 30 (19 to 67)
Equipment £1,500 (2%) £2,600 (4%) £1,800 (1%) £ 0 (0%) £0 (0%) £1500 (0 to 2,600) 1 (0 to 4)
External consultancy £18,145 (28%) £3,000 (5%) £28,120 (21%) £7,750 (19%) £55,544 (67%) £18,145 (3,000 to 55,544) 21 (5 to 67)
Consumables £25,850 (40%) £47,800 (72%) £13,666 (10%) £6,212 (16%) £10,002 (12%) £13,666 (6,212 to 47,800) 16 (10 to 72)
Total £65,375 £66,150 £131,776 £39,914 £82,550 £66,150 (39,914 to 131,776)
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Table 3 Clinical Trial Unit (CTU) job titles as submitted by nine CTUs
CTU Job titles submitted
Sheffield QA
Trial Manager
Data Manager
Senior Statistician
Junior Statistician
RA
Administrator
CTU Advice
Clerical
Birmingham PC-CRTU Quality Assurance Team
Trial Management
Data Manager
Statistics
Programming
CTEU Bristol Unit director
Unit manager
Research fellow
Research associate (coord)
Research assistant (coord)
Assistant coordinator
Administrator
Statistican (RF)
Statistician (RAassoc)
Statistician (Rassis)
Database manager
Research sister
Research nurse
Leeds CTU Statistician
Head of Trial Management,
Senior Trial Manager, Senior Trial
Co-ordinator
Trial Co-ordinator /Trial
Management Assistant
Clinical Trial Associate
Senior Data Manager
Data Management Assistant /
Data Entry Clerk
Information Systems
(programmer)
MRC CTU Project Lead
Programme Lead
Senior Statistician
Junior Statistician
Trial Physician
Clinical Projects Manager/Clinical
Operations Manager
Table 3 Clinical Trial Unit (CTU) job titles as submitted by nine CTUs
(Continued)
Trial Manager
Data Manager
Trial Assistant
(Senior) analyst programmer
Clinical Data Systems Manager
Data scientist
Research administrator
Newcastle CTU Statisticians
Data managers
Senior Trial Manager.
Trial Manager
Oxford CTSU Chief & Principal Investigators
Statistician
Trial Coordinator
Unit administrator
Contracts specialist
Clinical fellow
Training & monitoring
coordinator
Monitors
Supplies coordinator
Trial Manager
Trial administrator
Senior System Developer
Laboratory manager
Validation coordinator
Database administrator/IT
support
Health economist
Penninsula CTU Statistician
Trial Manager 1
Trial Manager 2
Data Manager 1
Data Manager 2
Data Programmer
Data Assistant 1
Data Assistant 2
Unit Coordinator
Trials Secretary
Southampton CTU Statistician/s
Senior Clinical Trials Manager
Clinical Trials Manager
Clinical Trial Coordinator
Data Manager
Data Officer
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(minutes, 20 March 2013, 15 July 2013, 2 October
2013 and 9 October 2013).
A second limitation is the extent to which costing of
the vignette by a CTU followed processes that would
have been used when costing an actual application for
funding for a trial. The formatting of the costs that were
reported by CTUs and details provided in subsequent
interviews demonstrated that the costs had been gener-
ated by staff familiar with CTUs’ usual costing processes
and experienced in applying them. However, the exercise
could not reproduce all of the formal steps for an actual
grant submission and it is possible that further checks,
required as part of approving a grant for actual submis-
sion, might have led to some revisions.
Findings in the context of previous trial literature/
discussion of findings
Our findings confirm that, for some trial activities – for
instance statistical support – there is remarkable similar-
ity in approaches to costing between CTUs. Also, despite
the differences in headline CTU costs, even the lowest
CTU costs exceeded £0.5 m. We mention this figure
because some funding opportunities invite applications
for nonpilot trials and, nevertheless, specify this, or a
lower figure, as a funding ceiling; specifying a ceiling in
this way tends to lead to trial budgets just under the
ceiling but which are not credible.
Similarity may arise either because the underlying costs
of an activity are, indeed, similar across CTUs or just
because CTUs have adopted a similar model for costing –
potentially, communicated from one CTU to another
because ‘that’s what the funder will accept’. The extent to
which CTUs cost planned research at the level of the task
was discussed, and was observed to vary; some did this (al-
beit, not with the granularity a CRO would use) and others
relied on standard costing templates in which many ele-
ments can vary only at the margins from project to project.
Several members argued that task-based costing is difficult
and time-consuming to do, and not necessarily predictive
of the actual work required on a project.
This study has begun the process of documenting real
differences in the activities and associated costs which
CTUs feel are necessary to deliver a particular trial, and
how they express those requirements. The differences in
role nomenclature (see Table 3), the scale at which differ-
ent units report allocating activity and costs – at the level
of the job family (e.g. study management), the role (e.g.
study manager or research assistant) or the task (e.g. site-
monitoring visit) – presented a barrier in comparing role
delineation and task allocation between units. By allowing
some CTUs to complete this exercise using discrete job
categories, and others using job families, the responses
may reflect disparate staff profiles. Even if this could be
ignored, further validation of the data would be required
before meaningful conclusions on comparative role delin-
eation can be drawn. For instance, six out of nine units
responding to the exercise did not declare that any tasks
from the list were associated with a quality assurance
(QA) officer, although in at least one case this is because
they had never been able to fund a formal QA role from
either core or grant funding.
The findings provide an empirical basis for what was
reported anecdotally at the outset. First, there are local
idiosyncrasies in resource need, estimation and alloca-
tion. This should be unsurprising given the different his-
tories behind CTUs with some of the oldest coalescing
around one or more clinical investigators in a particular
disease area, and newer general-purpose or region-specific
CTUs often being created. For instance, most of the trials
Table 5 Consistency in role definition – roles combined in job
families
Role Consistency (kappa)
QA 0.01
Trial manager/RA 0.18
Data manager 0.30
Statistician 0.35
Administrative/clerical 0.12
CTU advice 0.09
CTU clinical trials unit, QA quality assurance, RA research assistant
Table 4 Consistency in role definition – roles as submitted
Role Consistency (kappa)
QA 0.01
Trial manager 0.14
Data manager 0.30
Senior statistician 0.36
Junior statistician −0.01
RA 0.02
Administrative 0.1
CTU advice 0.09
Clerical 0.11
CTU clinical trials unit, QA quality assurance, RA research assistant
Table 3 Clinical Trial Unit (CTU) job titles as submitted by nine CTUs
(Continued)
Clinical Trials Assistant
Quality & Regulatory Manager
Quality & Regulatory Officer
Clinical Research Fellow
Operations Director
Clinical Trials Unit Administrator
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managed by one CTU are collaborations with ‘in-house’
chief investigators who are closely involved in many as-
pects of their trials (see Additional file 3). In many other
CTUs, collaborations with external, ‘client’ chief investiga-
tors are the norm, with more responsibility for trial man-
agement falling on senior CTU staff.
Second, the demands of project implementation fluc-
tuate in real life unpredictably, more than can be reliably
estimated at the planning stage; maintaining fuzzy bound-
aries between roles allows less well-resourced units to re-
spond flexibly to project implementation, given the
capacity and expertise they have available at a particular
time. When compared, superficial differences in staff costs
sometimes appeared to even out in, within and between
job families. For instance, an employee with a particular
role at one CTU might have a relatively high salary but be
costed for a smaller proportion of time for the relevant
job family at another CTU.
Implications
These findings have implications for funders, HEIs and
CTUs. Should funders care about variations in costs, or
simply make a judgement about perceived value for
money? The answer may differ by funding opportunity,
since commissioned research topics usually attract com-
peting bids whereas researcher-proposed topics do not.
More fundamentally, judging value for money becomes
much more difficult if HEIs cross-subsidise CTUs or im-
pose financial constraints. When judging whether CTU
costs in a grant application are appropriate, funders
should bear in mind that most direct costs are requested
for good reason, e.g. to support activities required by
sponsors, and are relatively standard across CTUs (al-
though the activities required by sponsors may vary, e.g.
in relation to monitoring). CTUs should strive to pro-
vide as much information and detail on costs as possible
to ensure that funders have a transparent view.
The largest variations in costs are outside the control
of CTUs, arising from factors that are features of, or are
imposed by, host organisations. These include staff pro-
file, levels of indirect costs and access to core funding.
Levels of indirect costs have also attracted attention in
the USA where, between 2003 to 2012, indirect costs of
National Institute for Health-funded studies increased
by 16.9% compared with 11.7% for direct costs [48]. Calcu-
lation of indirect costs in the UK is complex but is, ul-
timately, a function of choices made by HEIs when they
interpret TRAC guidance. For example, an institution
may require a grant budget to achieve a percentage
threshold of ‘cost recovery’ (indirect income), which could
be realised by assuming that researchers (who attract in-
direct income) rather than technical or administrative staff
(who do not) will carry out necessary activities. HEIs
can be penalised by the government for indirect costs
which are above the upper quartile of sector rates [40].
Finance officers at HEIs must approve grant applica-
tions at the time of submission; this requirement means
that an HEI can, in effect, prevent the submission of an
application if the HEI considers that the research will
not cover its costs [49].
Local idiosyncrasies of host institutions (minutes, 20
March 2013), as well as the diverse portfolios of CTUs
(minutes, 15 July 2013), make the adoption of a com-
mon, standardised costing template impossible. In prac-
tice, CTU-based researchers costing grant applications
expect the budget to reflect the needs of specific studies
(minutes, 15 July 2013). Workload models for organisa-
tions have principally been published by teams working
within the US National Institutes of Health, National
Cancer Institute and the National Cancer Institute of
Canada; these are primarily designed to estimate site
costs (more similar to templates increasingly adopted by
NHS hospitals to estimates sites costs), not CTU activities.
This literature supports the view that trials are increasing
in complexity but this conclusion may be influenced by
the predominant focus on cancer trials. Workload modes
are criticised for over-simplicity and are implicated in staff
burnout and poor quality standards [34, 36].
These criticisms resonate with researchers in CTUs
with responsibility for estimating trial management work-
load. Many trials commissioned by the UK NIHR involve
difficult-to-reach study populations and complex interven-
tions, making trial management workload unpredictable
[34]. CTU representatives in our group knew of costing
templates that had been developed over years and yet
which do not meet the needs of the trial team any more
reliably than costs generated by an experienced proposal
developer (minutes, 20 March 2013). It was also noted
that, when preparing a budget, a CTU starts with a staff
profile which cannot be changed quickly and easily to suit
the introduction of a standardised costing template (mi-
nutes, 20 March 2013). Recent attempts by three neigh-
bouring CTUs to build common approaches to costing
were reported to have failed for this and other reasons
(minutes, 20 March 2013). Consequently, CTUs involved
in this study reported relying on informal frameworks to
modify staffing by the scope, scale and stage of the trial
(minutes, 15 July 2013).
Projecting a timetable and recruitment for a trial are
critical to estimating a trial budget and are often uncer-
tain. There was scepticism among our group members
that national targets to bring down approval times were
uniformly successful [20], or robust to subversion [50–53].
The system for attributing costs in NHS R&D [54] often
resulted in long delays in the initiation of recruitment at
participating sites [18]. Delays at this early stage quickly
lead to a shortfall in recruitment. The planning fallacy,
that is, the tendency for people to ‘underestimate the
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time required to complete a project, even when they
have considerable experience’ [55], also plays a role in
the underestimation of variable costs, as a smaller than
anticipated fraction of patients screened typically enrol
in a study [56–59].
Despite growing evidence that an increase in central
monitoring and reduced site monitoring can safely re-
duce costs [45, 60–63], some sponsors and CTUs still
have reservations that central monitoring can reliably
maintain Good Clinical Practice (GCP)- and protocol-
compliance. Senior CTU staff who are writing proposals
should consider training in risk-based monitoring and
research should be considered which assesses the bar-
riers to, and facilitators of, uptake and implementation
of leaner monitoring strategies.
Conclusions
Some variation in costs is due to factors outside the con-
trol of CTUs such as access to core funding and levels
of indirect costs imposed by host institutions. CTUs
need to undertake a clear and transparent costing that
fully explains the resources required when submitting a
grant application to enable funders to make informed
decisions. Research is needed on barriers to implementing
evidence-based strategies which minimise costs, especially,
risk-based monitoring strategies.
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